Introduction
============

Alzheimer's disease is a complex syndrome characterized by a pleiotropic array of cognitive and behavioral symptoms ([@B36]). AD is mainly driven by the intraneuronal accumulation of β-amyloid, the extracellular formation of amyloid plaques and the appearance of intracellular neurofibrillary tangles composed of phosphorylated tau proteins. More recent lines of evidence support the idea that imbalance of β-amyloid production and clearance, along with phosphorylated tau and the interplay with other co-morbidity factors (metabolic, vascular, and inflammatory) work synergistically on a permissive condition represented by the aging brain to promote AD ([@B17]; [@B9]; [@B37]). Genetic and environmental factors also affect the onset and progression of the disease ([@B43]; [@B33]).

Genome-wide-association studies have identified and confirmed more than 20 genetic variants associated with higher susceptibility to develop Late-Onset Alzheimer Disease (LOAD) of the sporadic type ([@B49]). Among these, the 𝜀4 allele is a specific variant of the Apolipoprotein E gene (*APOE*-𝜀4) and a significant risk factor for AD ([@B35]; [@B5]). The physio-pathological function of *APOE* is complex ([@B29]; [@B42]) as the gene can interfere in many ways with the pillars of the disease ([@B28]; [@B43]). As an integral part of cellular membranes, *APOE*-𝜀4 can influence the amyloidogenic processing of the APP and impair its clearance from the brain ([@B37]). *APOE*-𝜀4 can also promote tau phosphorylation ([@B56]) and affect metabolic and vascular factors such as hypertension, diabetes mellitus, as well as the metabolic syndrome. All these factors synergistically modulate the AD onset and progression ([@B12]; [@B44]). For instance, these factors target the physiological functioning of the neurovascular unit and the BBB integrity. Interestingly, *APOE*-𝜀4 has been recently shown to converge on this critical step by affecting the operation of the neurovascular unit and promoting the breakdown of proteins responsible for the BBB integrity ([@B27]; [@B54]). However, despite the growing body of evidence on the *APOE*-related pathogenic mechanisms, a definitive molecular roadmap on the 𝜀4 haplotype targets remains elusive.

Recent data also indicate that a genetic variant of the *RNF219* gene may increase the risk for the AD ([@B34]). The rs2248663 A\>G (*RNF219*/G) polymorphism of the *RNF219* gene encoding for a member of the RNF family, has been associated with earlier onset of AD when working in synergy with the *APOE*-𝜀4 ([@B34]). This accelerating effect is not present in non-𝜀4 and *RNF219*/A carriers, thereby indicating that the two genes may work on common pathogenic pathways. In the study, we set out to integrate with new evidence the original *RNF219* findings ([@B34]) and evaluated whether *APOE*-𝜀4 and *RNF219*/G work in synergy or independently to affect the behavioral or cognitive features of patients affected by mild cognitive impairment (MCI) or AD. To that aim, we analyzed a comprehensive set of behavioral and cognitive profiles in two cohorts of female MCI or AD patients that included carriers or non-carriers of *APOE*-𝜀4 and *RNF219*/G.

Materials and Methods {#s1}
=====================

Study Population
----------------

The study was approved by the Institutional and Ethics Committee of the I.R.C.C.S. Santa Lucia-Rome. All procedures were conducted in accordance with principles expressed in the Helsinki Declaration. We recruited 173 total volunteers (mean age ± standard deviation = 74 ± 7) including 83 MCI and 90 AD patients. All included subjects signed an informed consent form before enrolment. Clinical evaluations were conducted by trained psychologists and AD specialists (neurologists and psychiatrists).

Neuropsychological Assessment
-----------------------------

Subjects were assessed with the following neuropsychological tests: MMSE, RAVL, Phonemic Verbal Fluency, CPMs, complex figure of Rey, Stroop test, and NPI. The main functional capacity was assessed by daily non-instrumental (ADL) ([@B47]) and instrumental activities (IADL) ([@B24]).

Mini Mental State Examination defines the global level of cognitive deterioration on a scale of 0--30 and targets general mental abilities, memory, attention, and language. A Score greater than or equal to 24 indicates the absence of cognitive deficits, scores ≤ 9 indicate the presence of severe cognitive deficits, scores between 10 and 18 indicate moderate cognitive deficits, and scores between 19 and 23 indicate mild cognitive deficits ([@B14]). RAVL allows a quantitative assessment of the ability of immediate and delayed recall ([@B39]). The CPMs measure fluid intelligence ([@B3]). The complex figure of Rey is a visual-perceptual test that investigates the complex perceptual organization and long-term visual memory ([@B38]). The Stroop test examines aspects of attention and executive functions ([@B45]). The NPI was developed to provide a way to assess neuropsychiatric symptoms and psychopathology of patients with AD and other neurodegenerative disorders ([@B10]). The NPI has been therefore employed to characterize neuropsychiatric profiles and is a structured interview that evaluates the following 12 behavioral domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavioral disturbance, eating disorders, and weight changes.

DNA Extraction
--------------

For gene variants analysis, genomic DNA was isolated from blood samples by the PureLink Genomic DNA Mini Kit (Life Technologies, Carlsbad, CA, United States), quantified by an Agilent 8453 Spectrophotometer (Agilent, Santa Clara, CA, United States) and stored at -20°C.

APOE Genotyping
---------------

*APOE* genotyping was performed by direct sequencing. PCR amplification of the region containing the rs429358 and rs7412 sites that determine the 𝜀2, 𝜀3, or 𝜀4 variants of the gene was carried out using the primers pair Forward: 5′-TAAGCTTGGCACGGCTGTCCAAGGA-3′ and Reverse: 5′-ACAGAATTCGCCCCGGCCTGGTACAC-3′, resulting in a 244 bp fragment ([@B18]). Purified PCR products were sequenced by the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA, United States) according to the manufacturer protocol. Sequence products were then separated on an ABI 3130xl automatic sequencer (Applied Biosystems, Paisley, United Kingdom) and analyzed using Sequencing Analysis Software (Applied Biosystems, Paisley, United Kingdom).

RNF219 Genotyping
-----------------

*RNF219* genotyping was carried out using High-Resolution Melting Analysis in 48-well plates on a StepOne^TM^ Real-Time PCR System run by StepOne Software v2.2.2 (Applied Biosystems, Paisley, United Kingdom) and analyzed with High-Resolution Melt Software v3.0.1 (Life Technologies, Carlsbad, CA, United States). We amplified a 103 bp fragment using the following primers pair: Forward: 5′-GGAAAAAGACAATGCAGGAAT-3′; Reverse: 5′-TTTTACCAAGGGCAACATTTC-3′. The PCR reaction, containing 20 ng of genomic DNA and the MeltDoctor HRM Master Mix (Applied Biosystems), according to the manufacturer protocols, was run as follow: enzyme activation at 95°C for 10 min; 40 cycles of denaturation and extension at 95°C for 15 s and 60°C for 1 min; melt curve with a denaturation at 95°C for 10 s, annealing at 60°C for 1 min, high resolution melting from 60 to 95°C with a ramp rate of 0.3% and final re-annealing at 60° C for 15 s. Fluorescence signals were measured during the amplification and melting steps.

Statistical Analysis
--------------------

*APOE* and *RNF219* genotypic and allelic frequencies of female MCI and AD patients were calculated as previously described ([@B48]). For statistical analysis, we separated the MCI and AD cohorts in carriers and non-carriers of the two allelic variants 𝜀4 and G. Allele frequencies of both *APOE* and *RNF219* polymorphisms were assessed for Hardy--Weinberg equilibrium (HWE) using a chi-square (χ^2^) test with significance set at *p* \< 0.05 ([@B48]).

One-way analysis of variance (ANOVA) followed by Fisher least significant difference (LSD) *post hoc* test was performed to investigate the significance of differences between age, education levels, MMSE corrected for age and education levels, the reported (by the patient or caregivers) age of appearance of the first symptom for MCI subjects, and age of onset for AD patients. Levene test was performed for assessment of homoscedasticity of the groups. Kruskal--Wallis test followed by multiple comparison of mean ranks was performed when the variances between groups were non-homogeneous.

Analysis of covariance (ANCOVA) was performed using a general linear model (GLM) approach and controlling for age and education level. *APOE* and *RNF219* genotypes were the independent factors, and the neuropsychological scores were the dependent variables. The main and interaction effects of the APOE and RNF219 genotypes were evaluated. The employed ANCOVA model is as follow: Y~i~ = β~0~ + β~1~ (age~i~) + β~2~ (education level~i~) + β~3~ (*APOE* genotype~i~) + β~4~ (*RNF219* genotype~i~) + β~5~ (*APOE* genotype~i~ × *RNF219* genotype~i~) + ε~i~, where Y~i~ indicates the specific i^th^ neuropsychological score, β~0~ is the intercept, and ε~i~ is the error term associated with the model. In the case of ordinal variables or when the assumption of the homogeneity of the variance was rejected by the Levene test, the ART procedure was applied ([@B50]; [@B13]). Multiple comparisons were performed using Fisher LSD *post hoc* test.

In all cases, *p*-values were corrected for multiple comparisons using the Benjamini--Hochberg correction at a false discovery rate (FDR) of 5%. *p*-Values \< 0.050 were considered statistically significant. Statistical analysis was performed using Statistica 6.0 software (Statsoft, Tulsa, OK, United States).

Results
=======

Demographic and Clinical Features of MCI and AD Cohorts
-------------------------------------------------------

The demographic and clinical characteristic of the study groups in the MCI or AD cohorts are shown in **Table [1](#T1){ref-type="table"}**. The study subgroups were matched for age, education levels, and MMSE scores as well as for the reported age of the first symptoms (in the case of MCI subjects) or age of onset (in the case of AD patients).

###### 

Demographic and clinical features of the study groups.

  Characteristic                                    MCI                       Levene test, *p*              One-way ANOVA or Kruskal--Wallis test, *p*                                     
  ------------------------------------------------- ------------------------- ----------------------------- ------------------------------------------------ --------------------- ------- -------
  Number of participants                            5                         31                            10                                               37                            
  Age, years; mean (SD)                             72 (7)                    71 (7)                        69 (7)                                           73 (6)                0.80    0.34
  Education level, mean (SD)                        9 (5)                     9 (5)                         6 (3)                                            7 (3)                 0.060   0.084
  Reported age of first symptom, years; mean (SD)   70 (8)                    68 (7)                        67 (7)                                           71 (6)                0.76    0.39
  MMSE, mean (SD)                                   25.5 (0.9)                25 (2)                        27 (1)                                           26 (2)                0.069   0.22
                                                                                                                                                                                           
  **Characteristic**                                **AD**                    **Levene test, *p***          **One-way ANOVA or Kruskal--Wallis test, *p***                                 
                                                    ***APOE*-*𝜀4* carrier**   ***APOE*-*𝜀4* non-carrier**                                                                                  
                                                    ***G carrier***           ***G non-carrier***           ***G carrier***                                  ***G non-carrier***           
                                                                                                                                                                                           
  Number of participants                            8                         26                            10                                               46                            
  Age, years; mean (SD)                             79 (5)                    74 (8)                        79 (9)                                           77 (8)                0.41    0.19
  Education level (years in school), mean (SD)      7 (4)                     9 (5)                         6 (4)                                            7 (3)                 0.053   0.091
  Age of onset, years; mean (SD)                    77 (5)                    72 (7)                        77 (9)                                           75 (8)                0.52    0.18
  MMSE, mean (SD)                                   21 (5)                    20 (5)                        17 (7)                                           20 (4)                0.41    0.21

Data are depicted as means and standard deviations (SD). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Fisher least significant difference

post hoc

test or Kruskal--Wallis test followed by multiple comparison of mean ranks. Levene test was performed for assessment of homoscedasticity of the groups. False discovery rate (FDR) corrected

p-

values \< 0.050 are shown in bold. MCI, patients with mild cognitive impairment; AD, patients with Alzheimer's disease; MMSE, mini-mental state examination score corrected for age and education levels; G carrier, RNF219/G polymorphism carrier, G non-carrier, RNF219/G polymorphism non-carrier; APOE genotype, APOE-𝜀4 genotype; 𝜀4 carrier, APOE-𝜀4 genotype carrier; 𝜀4 non-carrier, APOE-𝜀4 genotype non-carrier.

Distribution of *APOE* and *RNF219* Genotypes in the MCI and AD Cohorts
-----------------------------------------------------------------------

The distribution of *APOE* and *RNF219* genotypes and relative frequencies in MCI and AD patients are shown in **Table [2](#T2){ref-type="table"}**. Genotypes were in the Hardy--Weinberg equilibrium in MCI (*APOE p* = 0.064; *RNF219 p* = 0.36) and AD (*APOE p* = 0.64; *RNF219 p* = 0.29) patients.

###### 

Allele and genotype frequencies of APOE and RNF219 polymorphisms in the MCI and AD groups.

                                        *MCI* (*n* = 83)   *AD* (*n* = 90)                        
  ------------------------------------- ------------------ ----------------- ------ ------- ----- ------
  *APOE 𝜀2/𝜀3/𝜀4 genotypes*             𝜀2/𝜀2              0                 0      𝜀2/𝜀2   0     0
                                        𝜀2/𝜀3              4                 4.8    𝜀2/𝜀3   2     2.2
                                        𝜀3/𝜀3              43                51.8   𝜀3/𝜀3   54    60
                                        𝜀3/𝜀4              34                41     𝜀3/𝜀4   31    34.4
                                        𝜀4/𝜀4              0                 0      𝜀4/𝜀4   2     2.2
                                        𝜀2/𝜀4              2                 2.4    𝜀2/𝜀4   1     1.2
  *APOE 𝜀2/𝜀3/𝜀4 alleles*               𝜀2                 6                 3      𝜀2      3     2
                                        𝜀3                 124               75     𝜀3      141   78
                                        𝜀4                 36                22     𝜀4      36    20
  *RNF219 rs2248663 A \> G genotypes*   A/A                68                81.9   A/A     72    80
                                        A/G                15                18.1   A/G     18    20
                                        G/G                0                 0      G/G     0     0
  *RNF219 rs2248663 A \> G alleles*     A                  151               91     A       162   90
                                        G                  15                9      G       18    10

Effects of the *APOE* and *RNF219* Genotypes on Behavioral Features of MCI Subjects
-----------------------------------------------------------------------------------

Our study revealed that, in MCI subjects, the anxiety-related NPI score depends on the interaction between *APOE* and *RNF219* genotypes (*p* = 0.003) (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). The *APOE* genotype alone showed a trend toward significant effect on the same NPI score (*p* = 0.074) (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). In contrast, we did not find significant effects of age or education on the anxiety trait (*p* = 0.063 and 0.16, respectively).

*Post hoc* multiple comparisons showed that MCI 𝜀4/G carriers displayed increased levels of anxiety compared to other groups of patients. In fact, MCI patients carrying the 𝜀4/G alleles show higher levels of anxiety \[median (interquartile range): 6 (6--9)\] compared to MCI 𝜀4/A carriers \[median (interquartile range): 2 (0--4); *p* = 0.009\], non-𝜀4/A carriers \[median (interquartile range): 2 (0--4); *p* = 0.017\] and non-𝜀4/G carriers \[median (interquartile range): 1 (0--2.75); *p* = 0.009; **Figure [1](#F1){ref-type="fig"}**\].

![Apolipoprotein E (APOE) and RNF219 interaction in the modulation of anxiety of MCI subjects. Box plots show a comparison of anxiety scores and statistical differences set at *p* \< 0.05. Squares depict the mean values. The central horizontal bars represent the median values. The lower and the upper limits of the box represent the first and the third quartiles, respectively. Circles represent the minimum and maximum values of anxiety scores. Note that 𝜀4/G carriers show increased anxiety-related NPI scores compared to 𝜀4/A carriers (*p* = 0.009), non-𝜀4/A carriers (*p* = 0.017), and non-𝜀4/G carriers (*p* = 0.009). ^∗^Indicate statistically significant differences.](fnagi-10-00092-g001){#F1}

In contrast, we did not find significant main and/or interaction effects of *APOE* and *RNF219* variants on the other neuropsychological scores (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**).

Effects of the *APOE* and *RNF219* Genotypes on Behavioral Features of AD Patients
----------------------------------------------------------------------------------

In the case of AD patients, we found that *RNF219* variants had significant effects on anxiety-related NPI scores (*p* = 0.015). Similarly to the MCI group, in the AD cohort, we found that 𝜀4/G carriers show higher anxiety-related NPI scores \[median (interquartile range): 5.50 (1.75--8.25)\] compared to 𝜀4/A \[median (interquartile range): 0.5 (0--5.5); *p* = 0.041; **Figure [2](#F2){ref-type="fig"}**\] and non-𝜀4/A carriers \[median (interquartile range): 0 (0--2.75); *p* = 0.030; **Figure [2](#F2){ref-type="fig"}**\].

![Apolipoprotein E and RNF219 interaction in the modulation of anxiety of AD patients. Box plots show a comparison of anxiety NPI scores and statistical differences set at *p* \< 0.05. Squares depict the mean values. The central horizontal bars represent the median values. The lower and the upper limits of the box represent the first and the third quartiles, respectively. Circles represent the minimum and maximum values of anxiety scores. Note that 𝜀4/G carriers show higher anxiety-related NPI scores compared to 𝜀4/A (*p* = 0.041) and non-𝜀4/A carriers (*p* = 0.030). ^∗^Indicate statistically significant differences.](fnagi-10-00092-g002){#F2}

As for MCI subjects, we did not find any significant differences in other neuropsychological scores of the AD cohort (**Supplementary Table [S2](#SM2){ref-type="supplementary-material"}**).

Discussion
==========

In the study we explored whether *APOE*-𝜀4 and *RNF219*/G work in synergy or independently to affect the behavioral or cognitive features of MCI and AD patients ([@B34]).

In a preliminary phase of the study, we attempted to evaluate the synergistic effects of *APOE* and *RNF219* variants on behavioral and cognitive traits of male and female MCI or AD patients. However, after genotyping, we found that the sample size was too small to evaluate the effects of RNF genotype in males. Therefore, the study was redirected to investigate the impact of *APOE*-ε4 and *RNF219*/G only in female patients. We acknowledge that this is a limitation of our study and further studies will need to address effects on male patients.

In the study, we found that the *RNF219*/G variant, in synergy with the *APOE*-ε4 allele, amplifies the anxiety-related NPI scores. These scores are higher in *APOE*-𝜀4 and *RNF219*/G carriers of the MCI or AD cohorts (**Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}**).

Anxiety disorders are common late-life psychiatric features and have been associated with lower cognitive performance in older adults ([@B4]). Several lines of evidence support the modifying effect of the *APOE*-𝜀4 status on the AD neuropsychiatric symptoms ([@B46]). Reports indicate that anxiety and other behavioral symptoms are more prominent and severe in the population of female AD patients who are *APOE*-𝜀4 carriers ([@B41]; [@B52]), thereby supporting the notion of a relationship between the interaction of *APOE*-𝜀4 and gender in the phenotypical shaping of the AD-related behavioral features. The precise biological underpinning of the phenomenon is difficult to be identified. One possibility relies on the role played by estrogens in the disease progression of female patients. These hormones affect the synaptic plasticity of the AD brain as well as shape the response to AD-related pathology ([@B53]; [@B7]; [@B22]; [@B23]). Hormonal changes can act on neurotrophic mechanisms and be responsible for behavioral symptoms. For instance, in females, decreased peri-menopausal levels of estrogens have been suggested to favor the onset and progression of dementia-related depression and anxiety ([@B1]). These estrogen-related effects can amplify the activity of *APOE*. In fact, it is well-known that *APOE*-𝜀4 allele acts as a negative modulator of neuropsychiatric features in AD patients ([@B40]; [@B41]; [@B30]). Moreover, levels of estradiol are known to be influenced by the expression of the *APOE*-𝜀4 allele and promote a worsening of neuropsychiatric symptoms in female *APOE*-𝜀4 carriers ([@B51]). Surprisingly, we did not find significant effects of the *APOE*-𝜀4 allele on neuropsychological features such as apathy, aggressiveness, and depression. These symptoms have been previously shown in MCI or AD patients ([@B31]). A possible explanation of these divergent results may depend on the fact that our study has evaluated only female subjects while others have investigated mixed groups that included female and male patients.

The neurobiological effects of *RNF219* remain most unexplored. *RNF219* belongs to a family of proteins pleiotropically involved in many cellular functions. Some RNF proteins have been shown to modulate myelin formation ([@B19]) and the stability of GABAergic synapses ([@B20]). These proteins interfere with the activation of the ubiquitin system ([@B21]), a crucial mechanism for neuronal demise ([@B55]). A role for selected RNF proteins has also been proposed in neurodegenerative processes ([@B32]; [@B26]). In that regard, several genetic variants at the *RNF219* locus have been associated with the presence of cognitive deficits, brain atrophy and lipid deregulation ([@B2]; [@B8]; [@B15]). Of note, the *RNF219*/G variant has been recently associated with an earlier onset of AD ([@B34]).

Interestingly, recent studies in MCI patients have reported a positive relationship between the presence of high levels of anxiety and the likelihood of conversion to AD. Although the issue remains controversial ([@B11]; [@B6]), it has been shown that anxiety is associated with the earlier conversion to AD ([@B16]; [@B25]). Therefore, our findings allow the speculation of a potential correlation between anxiety, RNF219/G, *APOE*-𝜀4 and the conversion to AD.

In our study, we did not find any significant correlation between the anxiety levels and an earlier onset age for the first cognitive symptoms for MCI subjects or AD clinical signs (data not shown). *RNF219*/G has been shown to favor an earlier presentation of the disease in AD patients who are carriers of the polymorphism. The discrepancy with our study may be related to the small sample size of our female study groups and/or a gender effect. Our findings instead show the presence of higher anxiety levels in patients who are carrying *APOE*-𝜀4 and *RNF219*/G. This result may support the idea of a synergistic effect of these alleles on the behavioral alteration of the disease. Future studies are needed to clarify whether and how *RNF219*/G plays in synergy with the gender and *APOE*-𝜀4 status to affect the neurodegenerative processes underlying dementia.
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###### 

Summary data and Analysis of Covariance (ANCOVA) of neuropsychological scores in MCI subjects. ANCOVA was performed in order to evaluate the main and interaction effects of APOE and RNF219 genotype controlling for age and education level. Significant *p*-values, corrected for multiple comparisons using the Benjamini--Hochberg correction at a false discovery rate (FDR) of 5%, are shown in bold.

###### 

Click here for additional data file.

###### 

Summary data and analysis of covariance (ANCOVA) of neuropsychological scores in AD patients. ANCOVA was performed in order to evaluate the main and interaction effects of APOE and RNF219 genotype controlling for age and education level. Significant *p*-values, corrected for multiple comparisons using the Benjamini--Hochberg correction at a false discovery rate (FDR) of 5%, are shown in bold.

###### 

Click here for additional data file.

AD

:   Alzheimer disease

APOE

:   apolipoprotein E

APP

:   amyloid precursor protein

ART

:   Aligned Rank Transformation

BBB

:   blood--brain barrier

bp

:   base pair

CPM

:   Colored Progressive Matrices

GWASs

:   genome-wide-association studies

MCI

:   mild cognitive impairment

MMSE

:   Mini Mental State Examination

NPI

:   Neuropsychiatric Inventory

PCR

:   polymerase chain reaction

RAVL

:   Rey Auditory Verbal Learning

RNF

:   Ring Finger Protein

[^1]: Edited by: Mohammad Amjad Kamal, King Abdulaziz University, Saudi Arabia

[^2]: Reviewed by: Khyobeni Mozhui, University of Tennessee Health Science Center, United States; Davide Ragozzino, Sapienza Università di Roma, Italy

[^3]: ^†^These authors have contributed equally to this work.
